Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10573247		
	Filing Date		2006-03-23		
First Named Inventor Ree		Reed	Gamble		
	Art Unit		NYA		
	Examiner Name	Not Y	ret Assigned		
	Attorney Docket Number		330499.00050		

U.S.PATENTS					Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6037280	A	2000-03-14	Edwards et al.	
	2	4861651		1989-08-29	Goldenhersh	
	3	5166007	А	1992-11-24	Smith et al.	
	4	5414913	А	1995-05-16	Hughes	
	5	5503917	A	1996-04-02	Hughes	
If you wis	n to a	dd additional U.S. Pater			lease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					
If you wis	n to a	l dd additional U.S. Publi:	shed Ap	plication citation	n information please click the Ad	d button. Add
				FOREIGN PAT	TENT DOCUMENTS	Remove

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number Filing Date First Named Inventor Reed		10573247	
		2006-03-23	
		Gamble	
Art Unit		NYA	
Examiner Name Not Y		et Assigned	
Attorney Docket Numb	or	330499 00050	

Pages,Columns,Lines

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	where Relevant Passages or Relevant Figures Appear	Τs
	1	60-069014	JP	A	1985-04-19	Nitto Electric Company Limited		
	2	2004-149430	JP	A	2004-05-27	Kanebo Limited		Ø
	3	2004/110323	wo	A1	2004-12-23	Beatrice Pfister		
	4	02/059407	wo	A1	2002-08-01	E.I. Du Pont De Nemours And Company		
	5	96/25549	wo	A1	1996-08-22	CIBA-GEIGY AG		
	6	94/17135	wo	A1	1994-08-04	Maximilian Mutzhus		
	7	94/04515	wo	A1	1994-03-03	Rapelle PTY Limited		
	8	0 919 660	EP	A2	1999-06-02	Milliken Research Corporation		
If you wis	h to a	dd additional Foreign P				ease click the Add butto		_
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner	Cite					the article (when approp		Т5

(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),

publisher, city and/or country where published.

Initials* No

Application Number		10573247
Filing Date		2006-03-23
First Named Inventor Reed		Gamble
Art Unit		NYA
Examiner Name Not Y		et Assigned
Attorney Docket Number		330499.00050

	1	Pate	nt Abstracts of Japan for JP 60-969014, published April 19, 1985				
	2	Pate	nt Abstracts of Japan for JP 2004-149430, published May 27, 200-	4			
	3	Intern	national Search Report from the International Search Authority for	PCT/GB2004/004034			
If you wish to add additional non-patent literature document citation information please click the Add button Add							
EXAMINER SIGNATURE							
Examiner	Examiner Signature Date Considered						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Code of USPTO Platest Documents at swerup(SPTO_GOV) or MPEP 901.04. Enter office that issued the document, by the hoveleter of platest platest platest or the platest platest or the platest platest

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number Filing Date First Named Inventor Reed		10573247
		2006-03-23
		Gamble
Art Unit		NYA
Examiner Name Not Y		et Assigned
Attorney Docket Numb	er	330499.00050

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 a	and 1.98 to make	the appropriate selection(s):
---------------	------------	------------------	-------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement.

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew J. Bateman/	Date (YYYY-MM-DD)	2006-07-18
Name/Print	Andrew I Reference	Registration Number	45573

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenar's Office, and Superiment of Commence, P. 0. Bot 1450, Alexandria, V.32.511-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2044 and 2046. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.